HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online August 14 in ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

Desmoplastic melanoma (DM) is a distinct and uncommon variant of cutaneous melanoma, distinguished by its abundant fibrous stroma and spindle-shaped melanocytes. Recent investigations have ...

Desmoplastic melanoma (DM) is a rare subtype of melanoma which carries a high tumor mutation burden and is found in highly sun-exposed areas. Although many cutaneous melanomas are pigmented, DM is ...

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system attack cancer cells, can ...

Other variants such as amelanotic melanoma (a melanoma that produces no pigment and presents as a red patch or bump), desmoplastic melanoma (presents as a white scar-like bump), and nevoid ...

Purpose Previous studies have established that patients with desmoplastic melanoma (DM) have thicker primary tumors. Consequently, comparisons with other forms of melanoma have been strongly biased by ...

Amelanotic melanoma: the great masquerader. J Am Acad Dermatol. 2000;42 (5 Pt 1):731-734. Elmets CA, Ceilley RI. Amelanotic melanoma presenting as pyogenic granuloma. Cutis. 1980;25:164-166, 168.